CTOs on the Move

Contego Medical

www.contegomedical.com

 
Contego Medical, founded in 2005, has developed a family of novel emboli protection devices. The main feature of each device is that the treatment portion (i.e., balloon or stent) is on the same catheter as the embolic protection device, thus coupling the two together. This device can act as an angioplasty balloon with an integrated emboli protection device. If a stent is mounted on the balloon, it can serve as a stent with an integrated emboli protection device. We know that embolization occurs with all angioplasty and stenting procedures. It is usually hard to predict which ones will result in clinical ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Contego Medical raised $22M on 01/13/2020

Similar Companies

EvoEndo

EvoEndo develops systems that enable unsedated endoscopic procedures through a combination of sterile single-use, multi-specialty flexible endoscopes; VR-based patient distraction; and a comprehensive software integration platform.

Safecross First Aid

Safecross First Aid Ltd. is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Summit VetPharm

Summit VetPharm is a Fort Lee, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zap Surgical Systems

Leveraging unique gyroscopic motion, ZAP-X® opens new frontiers in modern radiosurgery. Combining self-shielding technology with high dose rate linear-accelerator delivery, ZAP-X was created to safely treat more patients in more places.

Glaukos

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world`s leading causes of blindness. Glaukos has pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. The company launched the iStent Trabecular Micro-Bypass Stent, its first MIGS device, in the United States in 2012. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. Glaukos believes the iStent is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, the company completed an initial public offering and its shares are now traded on the New York Stock Exchange under the ticker symbol "GKOS". Founded in 1998, Glaukos is based in San Clemente, California.